Ruxolitinib


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Primary myelofibrosis; Postpolycythaemia vera myelofibrosis; Postessential thrombocythaemia myelofibrosis Initial dose is based on platelet count: >200,000/mm3: 20 mg bid; 100,000-200,000/mm3: 15 mg bid; 50,000-<100,000/mm3: 5 mg bid. Polycythemia vera In patients who are resistant or intolerant to hydroxyurea: Initial: 10 mg bid. Titrate doses based on efficacy and tolerability.
Dosage Details
Oral
Myelofibrosis, post-essential thrombocythaemia, Myelofibrosis, post-polycythaemia vera, Primary myelofibrosis
Adult: Initial dose is based on platelet count: >200,000/mm3: 20 mg bid; 100,000-200,000/mm3: 15 mg bid; 50,000-<100,000/mm3: 5 mg bid. Titrate doses based on efficacy and tolerability. Interrupt dosing if platelet count is <50,000/mm3 or absolute neutrophil count (ANC) <500/mm3. If response is insufficient and blood counts are adequate, doses may be increased by up to 5 mg bid. Max: 25 mg bid. Initial dose may be increased after the 1st 4 weeks of treatment and thereafter no more frequently than every 2 weeks. Discontinue if there is no improvement or reduction in spleen size after 6 months.

Oral
Polycythemia vera
Adult: In patients who are resistant or intolerant to hydroxyurea: Initially, 10 mg bid. Titrate doses based on efficacy and tolerability. Dose may be reduced if platelet count is <100,000/mm3 and Hb decreases below 12 g/dL. Interrupt dosing if platelet count is <50,000/mm3 or Hb <8 g/dL. If response is insufficient and blood counts are adequate, doses may be increased by up to 5 mg bid. Max: 25 mg bid. Initial dose may be increased after the 1st 4 weeks of treatment and thereafter no more frequently than every 2 weeks.
Special Patient Group
Patients taking strong CYP3A4 inhibitors or dual inhibitors of CY3A4 and CYP2C9 enzymes: Reduce initial unit dose by approx 50 %, given bid.
Renal Impairment
Primary myelofibrosis; Postpolycythaemia vera myelofibrosis; Postessential thrombocythaemia myelofibrosis
CrCl (mL/min) Dosage
15-29 Reduce initial unit dose (based on platelet count) by approx 50%, given bid.
30-59 Reduce initial unit dose (based on platelet count) by approx 50%, given bid.

Polycythemia vera
ESRD patients undergoing haemodialysis: 10 mg as a single dose or 5 mg 12 hrly, given after dialysis session.
CrCl (mL/min) Dosage
15-29 5 mg bid.
30-59 5 mg bid.
Hepatic Impairment
Primary myelofibrosis; Postpolycythaemia vera myelofibrosis; Post-essential thrombocythaemia myelofibrosis
Reduce initial unit dose by approx 50%, given bid.

Polycythemia vera
5 mg bid.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Pregnancy and lactation.
Special Precautions
Patient with TB or risk of TB, chronic hepatitis B virus infection. Patients taking strong CYP3A4 inhibitors or dual inhibitors of CY3A4 and CYP2C9 enzymes (e.g. fluconazole). Hepatic and moderate to severe renal impairment.
Adverse Reactions
Significant: Anaemia, thrombocytopenia, neutropenia; serious bacterial, mycobacterial, fungal, and viral infections (e.g. TB, herpes zoster, pneumonia, UTI); increased cholesterol and triglycerides, non-melanoma skin cancers (e.g. basal cell, squamous cell, Merkel cell carcinoma), progressive multifocal leukoencephalopathy (PML).
Cardiac disorders: Dyspnoea.
Gastrointestinal disorders: Diarrhoea, abdominal pain, constipation, nausea, flatulence, vomiting, gastrointestinal bleeding.
General disorders and administration site conditions: Fatigue, weakness.
Investigations: Increased ALT/AST.
Metabolism and nutrition disorders: Weight gain, hypercholesterolaemia, hypertriglyceridaemia, oedema.
Musculoskeletal and connective tissue disorders: Muscle spasm.
Nervous system disorders: Dizziness, headache, intracranial bleeding.
Psychiatric disorders: Insomnia.
Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, cough, epistaxis.
Skin and subcutaneous tissue disorders: Bruising.
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor CBC with differential (prior to therapy and every 2-4 weeks until doses are stabilised, then as clinically indicated), lipid parameters, hepatic and renal function, HBV-DNA titer; signs and symptoms of infections. Evaluate patients for presence of active or latent TB prior to treatment.
Overdosage
Symptoms: Myelosuppression (e.g. anaemia, leucopenia, thrombocytopenia). Management: Supportive treatment.
Drug Interactions
Increased plasma concentration with strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, indinavir, itraconazole, lopinavir, ritonavir, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole) and mild or moderate CYP3A4 inhibitors (e.g.  ciprofloxacin, erythromycin, amprenavir, atazanavir, diltiazem, cimetidine). Decreased plasma concentration with CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin). May increase plasma concentration of substances transported by P-glycoprotein and breast cancer resistance protein (e.g. dabigatran, ciclosporin, rosuvastatin, digoxin).
Food Interaction
Decrease plasma concentration with St. John’s wort. Increased plasma concentration with grapefruit or grapefruit juice.
Action
Description: Ruxolitinib is a selective inhibitor of Janus Associated Kinases (JAKs) 1 and 2. JAK 1/2 are tyrosine kinases which mediate the signalling of numbers of cytokines and growth factors that are important for haematopoiesis and immune function. Myelofibrosis and polycythaemia vera are known to be associated with dysregulation of JAK 1/2 thus ruxolitinib modulate the activity of the affected JAK 1/2.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: Within 1-2 hours.
Distribution: Volume of distribution: Myelofibrosis: 72 L; Polycythemia vera: 75 L.  Plasma protein binding: Approx 97%, mainly to albumin.
Metabolism: Metabolised in the liver mainly by CYP3A4, and minimally by CYP2C9 enzymes.
Excretion: Mainly via urine (74%, <1% as unchanged drug); faeces (22%, <1% as unchanged drug). Elimination half-life: Approx 3 hours (ruxolitinib); approx 5.8 hours (ruxolitinib + metabolites).
Chemical Structure

Chemical Structure Image
Ruxolitinib

Source: National Center for Biotechnology Information. PubChem Database. Ruxolitinib, CID=25126798, https://pubchem.ncbi.nlm.nih.gov/compound/Ruxolitinib (accessed on Jan. 23, 2020)

Storage
Store between 20-25°C.
This is a cytotoxic drug. Follow applicable procedures for receiving, handling, administration, and disposal.
ATC Classification
L01XE18 - ruxolitinib ; Belongs to the class of protein kinase inhibitors, other antineoplastic agents. Used in the treatment of cancer.
References
Anon. Ruxolitinib. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 03/04/2018.

Anon. Ruxolitinib. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/04/2018.

Buckingham R (ed). Ruxolitinib. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/04/2018.

Jakafi Tablet (Incyte Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/04/2018.

Joint Formulary Committee. Ruxolitinib. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/04/2018.

Ruxolitinib. Drugs and Lactation Database (LactMed) [Internet]. Bethesda, MD. U.S. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501922/. Accessed 03/04/2018.

Disclaimer: This information is independently developed by MIMS based on Ruxolitinib from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in